Inhibition of the MET Kinase Activity and Cell Growth in MET-Addicted Cancer Cells by Bi-Paratopic Linking.

@article{Andres2019InhibitionOT,
  title={Inhibition of the MET Kinase Activity and Cell Growth in MET-Addicted Cancer Cells by Bi-Paratopic Linking.},
  author={F. Andres and L. Iamele and T. Meyer and Jakob C St{\"u}ber and Florian Kast and E. Gherardi and H. Niemann and A. Pl{\"u}ckthun},
  journal={Journal of Molecular Biology},
  year={2019},
  volume={431},
  pages={2020-2039}
}
  • F. Andres, L. Iamele, +5 authors A. Plückthun
  • Published 2019
  • Chemistry
  • Journal of Molecular Biology
  • Abstract MET, the product of the c-MET proto-oncogene, and its ligand hepatocyte growth factor/scatter factor (HGF/SF) control survival, proliferation and migration during development and tissue regeneration. HGF/SF-MET signaling is equally crucial for growth and metastasis of a variety of human tumors, but resistance to small-molecule inhibitors of MET kinase develops rapidly and therapeutic antibody targeting remains challenging. We made use of the designed ankyrin repeat protein (DARPin… CONTINUE READING
    2 Citations

    References

    SHOWING 1-10 OF 70 REFERENCES
    Genetic targeting of the kinase activity of the Met receptor in cancer cells
    • 33
    • PDF
    Targeting MET in cancer therapy
    • 61
    Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
    • 56
    A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo
    • 310
    • PDF
    Targeting MET in cancer: rationale and progress
    • 335
    • PDF
    Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
    • G. Smolen, R. Sordella, +10 authors D. Haber
    • Biology, Medicine
    • Proceedings of the National Academy of Sciences of the United States of America
    • 2006
    • 486
    • PDF